What Is GHK-Cu?

1. How does GHK-Cu work?

GHK is a peptide made from three amino acids. It binds copper ions to form GHK-Cu. Researchers study how this complex changes the behavior of fibroblasts, which produce connective tissue, and keratinocytes, which make up much of the skin’s outer layer.

In Wegrowski and colleagues’ cell study, GHK-Cu increased production of certain glycosaminoglycans, molecules found in the material surrounding cells. The response peaked within a low concentration range and fell toward control levels at higher concentrations. More peptide did not keep producing a larger response.

Kang and colleagues also found increased proliferation and changes in attachment-related proteins in human keratinocyte cultures and reconstructed skin models. These experiments offer a biological reason to investigate skin repair. They cannot predict how much a person’s skin will change after using a serum.

Copper binding also does not make every copper-containing product equivalent. A copper supplement, copper fabric and GHK-Cu formulation have different compositions and delivery. Their results need separate testing.

2. Does GHK-Cu improve skin? The human studies

The clinical picture includes a positive cosmetic study and negative results in other skin settings. These studies tested different formulations and conditions, so they should not be averaged into a single success rate.

The wrinkle result supports further testing of topical GHK-Cu. The other trials prevent a broader claim that copper peptides reliably accelerate human wound healing. None of these studies tested subcutaneous injections for general recovery.

Where the “55.8% wrinkle reduction” comes from

The 2016 paper’s Table 2 gives the changes from baseline. In the 20-person vehicle-comparison group, measured wrinkle volume fell by an average of 24.1% on the active side and 15.0% on the control side. That is a 9.1-percentage-point difference.

The paper separately reports 55.8% as a relative between-treatment comparison. It does not mean the average participant’s wrinkle volume fell 55.8% from baseline. Researchers measured a selected wrinkle near the eye, so the result also cannot describe every wrinkle on the face.

The active serum contained both GHK-Cu and a lipid delivery system; the control lacked both. The methods assigned the active serum to the right side of the face. Those design choices limit how cleanly the study isolates GHK-Cu’s contribution. Its funding came from Snowberry New Zealand and Callaghan Innovation; the authors stated that Snowberry had no role in data collection, analysis or writing.

3. Topical GHK-Cu vs injections

A topical product has to deliver the ingredient through the skin barrier. In their preformulation research, Badenhorst and colleagues measured GHK-Cu’s solubility, stability and distribution between water and oil. Its strong preference for water helps explain why delivery through the skin’s lipid-rich barrier is a formulation problem.

A concentration on a label therefore gives only part of the information. The vehicle, stability and delivery system can affect exposure. Results from a studied serum cannot automatically be assigned to another cream or to powder mixed into a moisturizer.

Injecting changes the question to how the compound distributes, breaks down and affects tissues after administration. A skin-barrier limitation does not establish that an injection improves cosmetic outcomes. There is no reliable human head-to-head evidence showing that injectable GHK-Cu works better than topical GHK-Cu for skin aging.

The FDA identifies potential immune-reaction risks from aggregation and peptide-related impurities in compounded injectable GHK-Cu. It also notes limited human safety data. Cosmetic tolerance cannot settle those questions.

4. Does GHK-Cu regrow hair?

Two papers frequently used to support copper-peptide hair claims tested different materials:

AHK-Cu starts with alanine; GHK-Cu starts with glycine. The Pyo study found that AHK-Cu stimulated follicle elongation outside the body. Calling this “GHK-Cu regrows human hair” changes both the molecule and the experimental setting.

The human combination trial is closer to a practical hair-loss question, but it still does not validate a GHK-Cu serum or injection. Reliable clinical evidence has not established GHK-Cu alone as a substitute for established hair-loss treatment.

5. Can GHK-Cu tighten loose skin after weight loss?

Human trials have not established that GHK-Cu reduces excess skin after substantial weight loss. That includes weight loss with semaglutide or tirzepatide.

A change in a small facial wrinkle does not measure abdominal skin redundancy, upper-arm laxity or facial volume loss. The people, anatomy and outcomes differ from the cosmetic trial above. A useful study would recruit people after weight loss and measure laxity, excess skin and patient-reported function against a control treatment.

Before-and-after photos also need comparable body weight, lighting, pose and camera distance. If weight is still changing, photos cannot separate that change from a product’s effect. The existing wrinkle data offer no dependable estimate of how much loose skin might improve.

6. GHK-Cu, gene expression and longevity

The claim that GHK “resets thousands of genes” comes from gene-expression research. In a 2014 analysis, Pickart and colleagues examined three GHK profiles from the Connectivity Map database, generated in PC3 and MCF7 cancer cell lines.

Gene expression measures how actively cells read genes. Changing that activity does not rewrite DNA, prove a younger biological age or demonstrate longer life. The experiment also used GHK profiles, which should not be casually relabeled as evidence for a particular injectable GHK-Cu product.

There is newer lifespan research. Wen and colleagues’ May 2026 study reported longer lifespan and improved stress resistance in Caenorhabditis elegans, a microscopic worm used in aging research. The authors investigated mitochondrial function and DAF-16/SKN-1 signaling, pathways involved in stress responses.

That is a reason to continue preclinical research. It supplies no human lifespan estimate, validated biological-age reduction or anti-aging injection schedule. Counting affected genes cannot substitute for those outcomes.

7. GHK-Cu dosage, concentration and half-life

There is no validated injectable GHK-Cu dose or cycle for anti-aging, hair regrowth or injury recovery. The human topical studies cannot provide one. A percentage in a cream cannot be converted into milligrams injected under the skin because tissue exposure and bioavailability differ.

For cosmetics, the available comparisons also do not establish a universal best concentration. A “1% peptide complex” label may refer to a blend rather than 1% pure GHK-Cu; the manufacturer needs to specify what the percentage describes. The cell experiments above give no basis for assuming a higher concentration will produce a better result.

A dependable human subcutaneous half-life has not been established well enough to validate the schedules circulated in peptide forums. Clearance from blood, persistence in tissue and the duration of a biological response are separate measurements. A half-life model based on an assumed value cannot determine an effective or safe dosing interval.

8. GHK-Cu side effects and stacking

The eight-week cosmetic study reported one participant who stopped after minor skin reactions on both treatment sides. Symptoms resolved without treatment. Because the participant used different products on opposite sides, the report cannot identify GHK-Cu as the cause or establish a general irritation rate.

For injections, dependable adverse-event frequencies and long-term safety data are missing. FDA’s concerns include peptide clumping and impurities that could provoke immune reactions. A supplier’s purity percentage does not, by itself, establish the sterility, dose accuracy or clinical safety of a finished injectable product.

Blends marketed as “GLOW” commonly combine GHK-Cu with BPC-157 and TB-500; names and contents can vary. No reliable controlled human trial establishes that this combination improves skin or recovery more than its individual ingredients. Combining three compounds also makes a new symptom or apparent benefit harder to attribute.

Claims about cancer prevention or cancer risk need human outcome data. Gene-expression changes in cancer cells cannot establish that GHK-Cu prevents cancer, and the available studies do not settle the long-term safety of systemic use.

9. Is GHK-Cu FDA-approved? The 2026 update

GHK-Cu is not an FDA-approved drug for skin aging, hair loss or longevity as of September 20, 2026. Its use as a cosmetic ingredient does not establish approval for those medical claims.

The FDA’s May 14, 2026 compounding document put GHK-Cu for non-injectable routes back into Category 1, meaning under evaluation. The update followed clarification that a nominator intended to withdraw only its injectable nomination. The agency said it intended to consult its advisory committee before the end of February 2027.

That administrative change does not establish injectable safety or effectiveness. The FDA continues to describe specific safety concerns for injectable GHK-Cu.

10. How to judge GHK-Cu before-and-after claims

A useful report identifies the exact product, duration and outcome. “Better skin” could mean hydration, redness, wrinkle depth or a change in lighting. Those are different observations.

For someone already using a topical cosmetic, consistent photographs and a record of other skincare changes make the result easier to interpret. Keep the same lighting, camera distance, expression and time relative to cleansing or moisturizing. Record irritation as carefully as any improvement. The eight-week cosmetic study gives context for its own assessment window, not a guaranteed deadline for visible results.

When comparing a claim with a paper, match the molecule, route and measured outcome. A GHK-Cu serum study belongs beside a serum claim; an AHK-Cu follicle experiment cannot establish hair regrowth from GHK-Cu injections.

11. GHK-Cu FAQ

• What is GHK-Cu used for?

  GHK-Cu is used in cosmetic skincare and studied for tissue repair. Small topical studies suggest possible wrinkle benefits, but human evidence does not establish injectable GHK-Cu for recovery, hair regrowth or longevity.

• Is GHK-Cu the same as copper tripeptide-1?

  Copper tripeptide-1 is the common cosmetic ingredient name for GHK-Cu. GHK without copper, palmitoyl tripeptide-1 and AHK-Cu are different substances; their study results are not interchangeable.

• Does GHK-Cu reduce wrinkles by 55.8%?

  That figure came from a between-treatment comparison in a small 2016 study. Its table reported an average 24.1% reduction from baseline in wrinkle volume with the GHK-Cu serum and 15.0% with the control at eight weeks. It does not mean users lost 55.8% of their wrinkles.

• Does GHK-Cu regrow hair?

  Reliable human evidence has not established hair regrowth from GHK-Cu alone. A frequently cited laboratory study used AHK-Cu, a different copper peptide. A small human trial tested GHK combined with 5-aminolevulinic acid.

• Are GHK-Cu injections better than a serum?

  No reliable human head-to-head evidence establishes that injections improve skin more than topical GHK-Cu. Injecting changes exposure and introduces risks that a cosmetic study cannot assess.

• What is the recommended GHK-Cu dosage or cycle?

  There is no validated injectable anti-aging dose or cycle. A topical concentration cannot be converted into a subcutaneous dose, and existing research does not establish a universal best serum concentration.

• Can GHK-Cu tighten loose skin after weight loss?

  Human trials have not established that benefit. Measuring a facial wrinkle is different from measuring excess skin after substantial weight loss, including weight loss with semaglutide or tirzepatide.

• What are GHK-Cu's side effects?

  A small cosmetic trial reported one withdrawal after a skin reaction on both treatment sides, so the cause was unclear. Dependable side-effect rates for injections are unavailable. FDA flags potential immune reactions associated with aggregation and peptide impurities.

• Is GHK-Cu FDA-approved?

  GHK-Cu is not an FDA-approved anti-aging or hair-loss drug. FDA's May 2026 compounding update placed non-injectable GHK-Cu back under evaluation; that status does not approve a drug or authorize injectable anti-aging claims.

12. Sources